Skip to main content

Clinical trial MK-3475-B96/KEYNOTE-B96/ENGOT-ov65

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTEB96/ ENGOT-ov65)

Cancers
Organ Ovary
Trial status Trial closed for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Merck
EudraCT Identifier 2020-005027-37
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05116189
Last update